Home > Name List By g > Glycine,N-[(1R)-1-cyclohexyl-2-[(2S)-2-[[[[4-[(hydroxyamino)iminomethyl]phenyl]methyl]amino]carbonyl]-1-azetidinyl]-2-oxoethy...

CAS No 192939-46-1 , Glycine,N-[(1R)-1-cyclohexyl-2-[(2S)-2-[[[[4-[(hydroxyamino)iminomethyl]phenyl]methyl]amino]carbonyl]-1-azetidinyl]-2-oxoethyl]-,ethyl ester

  • Name: Glycine,N-[(1R)-1-cyclohexyl-2-[(2S)-2-[[[[4-[(hydroxyamino)iminomethyl]phenyl]methyl]amino]carbonyl]-1-azetidinyl]-2-oxoethyl]-,ethyl ester
  • Synonyms: Ximelagatran;Glycine,N-[(1R)-1-cyclohexyl-2-[(2S)-2-[[[[4-[(hydroxyamino)iminomethyl]phenyl]methyl]amino]carbonyl]-1-azetidinyl]-2-oxoethyl]-,ethyl ester; H376/95;Exanta;
  • CAS Registry Number:
  • Flash Point: °C
  • Boiling Point: °Cat760mmHg
  • Density: 1.35g/cm3
  • Refractive index: 1.635
  • Flash Point: °C
  • Molecular Weight: 0
  • InChI: InChI=1/C24H35N5O5/c1-2-34-20(30)15-26-21(17-6-4-3-5-7-17)24(32)29-13-12-19(29)23(31)27-14-16-8-10-18(11-9-16)22(25)28-33/h8-11,17,19,21,26,33H,2-7,12-15H2,1H3,(H2,25,28)(H,27,31)/t19-,21+/m0/s1
  • Molecular Formula: C24H35 N5 O5
  • Molecular Structure:CAS No:192939-46-1 Glycine,N-[(1R)-1-cyclohexyl-2-[(2S)-2-[[[[4-[(hydroxyamino)iminomethyl]phenyl]methyl]amino]carbonyl]-1-azetidinyl]-2-oxoethyl]-,ethyl ester

Select to

192939-46-1 XIMELAGATRAN

  • China Nanjing Chemlin Chemical Industry Co.,Ltd. [Manufacturer]
  • Tel: +86 25 8369-7070/ +86 138 51816776 (Mobile)
  • Fax: +86 25 8345-3275
  • Address: Rm.902 Longyin Plaza,
    No. 217 Zhongshan Rd.
    (N)Nanjing 210009,China null,nullChina
Contact Supplier

Select to

References of Glycine,N-[(1R)-1-cyclohexyl-2-[(2S)-2-[[[[4-[(hydroxyamino)iminomethyl]phenyl]methyl]amino]carbonyl]-1-azetidinyl]-2-oxoethyl]-,ethyl ester
Title: Ximelagatran
CAS Registry Number: 192939-46-1
CAS Name: N-[(1R)-1-Cyclohexyl-2-[(2S)-2-[[[[4-[(hydroxyamino)iminomethyl]phenyl]methyl]amino]carbonyl]-1-azetidinyl]-2-oxoethyl]glycine
Manufacturers' Codes: H-376/95
Trademarks: Exanta (AstraZeneca)
Molecular Formula: C24H35N5O5
Molecular Weight: 473.57
Percent Composition: C 60.87%, H 7.45%, N 14.79%, O 16.89%
Literature References: Orally active direct thrombin inhibitor; prodrug of melagatran, q.v. Prepn: T. Antonsson et al., WO 9723499; D. Gustafsson et al., US 5965692 (1997, 1999 both to Astra). CE determn in drug formulations: P. K. Owens et al., J. Pharm. Biomed. Anal. 27, 587 (2002). LC-MS determn in biological samples: M. Larsson et al., J. Chromatogr. B 783, 335 (2003). Clinical pharmacokinetics: K. Wahlander et al., Thromb. Res. 107, 93 (2002); in deep vein thrombosis: M. Cullberg et al., Clin. Pharmacol. Ther. 77, 279 (2005). Clinical study vs warfarin as thromboprophylactic: C. W. Francis et al., Ann. Intern. Med. 137, 648 (2002). Review of clinical experience in acute coronary syndromes: J. S. Kalus, M. F. Caron, Expert Opin. Invest. Drugs 13, 465-477 (2004); of clinical development: C. J. Boos et al., Eur. J. Int. Med. 16, 267-278 (2005).
Therap-Cat: Antithrombotic.
Keywords: Antithrombotic.